<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910361</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_NAFLD_IV</org_study_id>
    <nct_id>NCT03910361</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases</brief_title>
  <official_title>A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial
      to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and
      non-alcoholic fatty liver diseases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Evogliptin 5mg Group: Administration with Evogliptin 5mg and Placebo for 24weeks

        2. Pioglitazone 15mg Group: Administration with Pioglitazone 15mg and Placebo for 24weeks
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline intrahepatic fat (%)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline intrahepatic fat (%) after treatment with evogliptin or pioglitazone</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Evogliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evogliptin 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone 15mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin</intervention_name>
    <description>evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd</description>
    <arm_group_label>Evogliptin</arm_group_label>
    <other_name>Suganon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Gluconon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II diabetes mellitus

          -  Subjects who have not been taking any oral hypoglycemic agent within 8 weeks from
             screening or who have been taking metformin monotherapy at the same dose for more than
             8 weeks before screening

          -  Subjects with 6.5%≤HbA1c≤9.0% at screening

          -  Subjects with 20kg/m2≤BMI≤40kg/m2 at screening

        Exclusion Criteria:

          -  Type I diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus

          -  AST &gt; upper normal range*3

          -  Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption

          -  Subjects who experienced hypersensitivity reaction against DPP-4 inhibitors,
             thiazolidinediones

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung Wan Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung Dongsan University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Seoul ST.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>July 7, 2019</last_update_submitted>
  <last_update_submitted_qc>July 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

